|
Patent landscape, scope, and claims: |
United States Patent 5,958,951: Scope, Claim Architecture, and Landscape
What does US 5,958,951 claim in plain scope terms?
US 5,958,951 is a crystalline form patent centered on anhydrous crystalline R(-) tiagabine hydrochloride, identified by a KBr X-ray powder diffraction (XRPD) peak set. The claims then extend into process and therapeutic use via GABA uptake inhibition and pharmaceutical compositions.
The key claim elements are consistent across the independent thrust:
- Drug substance identity: R(-)-N-(4,4-di(3-methylthien-2yl)but-3-enyl)nipecotic acid hydrochloride (tiagabine hydrochloride, R(-) enantiomer)
- State: anhydrous crystalline
- Crystalline characterization: XRPD peaks at 6.4, 11.3, 13.0, 13.9, 15.0, 18.7, 19.4, 22.5, 23.7 (KBr method)
- Functional outcome: inhibiting GABA uptake in a mammal (method-of-use claims)
- Downstream product claims: composition and dosage unit claims
What is the claim-by-claim scope and how each claim narrows?
Claim 1 (core product-by-characterization)
Claim 1:
- Covers anhydrous crystalline R(-)-tiagabine hydrochloride
- Requires “substantially the following” XRPD peaks obtained with KBr:
- 6.4, 11.3, 13.0, 13.9, 15.0, 18.7, 19.4, 22.5, 23.7
Practical scope boundaries
- Must be anhydrous (presence of bound water can be used to avoid literal scope).
- Must be crystalline and match the XRPD peak fingerprint.
- The phrase “substantially” introduces flexibility, but the listed peak set is the anchor.
Claim 2 (product state refinement: “substantially free of bound organic solvent”)
Claim 2:
- Adds a further restriction to Claim 1:
- “substantially free of bound organic solvent”
- Requires the same XRPD peak list as Claim 1.
Impact
- Claim 2 targets forms contaminated with residual bound organics (e.g., residual solvents in the crystal lattice). A competitor can potentially design around by selecting crystallization/solvent systems producing crystals with different “bound solvent” status, though this depends on measurement and the meaning of “substantially free.”
Claim 3 (process claim anchored on precipitation)
Claim 3:
- Claims a process for preparing the same anhydrous crystalline R(-)-tiagabine hydrochloride
- The product produced must match the same XRPD peak set.
- Process steps:
- a) dissolving tiagabine hydrochloride in an aqueous hydrochloric acid solution
- b) precipitating tiagabine hydrochloride from that aqueous HCl solution
Impact
- A competitor can avoid literal infringement by changing core process logic (e.g., not using aqueous HCl as solvent medium, not using precipitation from aqueous HCl, or using alternative crystallization routes that yield the same XRPD form).
- However, because the claim ties product identity via XRPD peaks, “end-form” matching may matter in practice for enforcement, even when process details differ.
Claim 4 (composition claim: crystal + carrier)
Claim 4:
- A pharmaceutical composition comprising:
- a therapeutically effective amount of the crystalline salt of Claim 1
- plus a pharmaceutically acceptable carrier or diluent
Scope
- Covers formulation variants as long as they contain the Claim 1 crystal (anhydrous R(-)-tiagabine HCl with that XRPD fingerprint).
Claim 5 (dosage unit range)
Claim 5:
- Composition of Claim 4 in dosage unit form containing about 1.0–1500 mg active ingredients
Scope
- Very broad in the amount window. Design-around through lower doses could still fall outside “about,” but the window is wide.
Claim 6 (method-of-use: administering the crystalline salt)
Claim 6:
- Method of inhibiting GABA uptake in a mammal by administering an effective amount of the crystalline salt of Claim 1
Scope
- Directs at clinical/therapeutic use. It is typically harder to design around by formulation changes alone if the active crystalline form is used.
Claim 7 (method-of-use via composition)
Claim 7:
- Similar method of Claim 6 but uses:
- administering the pharmaceutical composition of Claim 4
Scope
- Captures both “drug substance” and “formulated product” usage.
How does the claim set create a layered infringement surface?
The patent’s structure is typical of crystalline form protection:
- Substance claim (Claim 1) by XRPD fingerprint and anhydrous status.
- Substance refinement (Claim 2) to exclude bound organics.
- Process claim (Claim 3) with a specific HCl precipitation logic tied to the same end-form XRPD.
- Formulation claims (Claims 4–5) using the Claim 1 crystal.
- Therapeutic method claims (Claims 6–7) tied to GABA uptake inhibition using that crystal or its composition.
Claim map (who is covered)
| Layer |
Claim(s) |
Covered parties/products |
Main trigger |
| Crystal substance |
1 |
Active ingredient as solid |
Anhydrous + XRPD peak set (KBr) |
| Crystal refinement |
2 |
Active ingredient with low bound organics |
“substantially free of bound organic solvent” + same XRPD |
| Manufacturing |
3 |
Process route to that crystal |
Dissolve tiagabine HCl in aqueous HCl; precipitate from same |
| Formulation |
4–5 |
Dosage units |
Contains Claim 1 crystal + carrier; 1–1500 mg window |
| Use |
6–7 |
Prescribing/administration workflow |
GABA uptake inhibition with Claim 1 crystal/composition |
What is the practical enforcement narrative of the XRPD peak requirement?
The patent’s enforceability hinges on analytical matching to:
- XRPD peaks at 6.4, 11.3, 13.0, 13.9, 15.0, 18.7, 19.4, 22.5, 23.7
- KBr method
- and anhydrous status
This means the patent typically reads on product families defined by solid-state identity rather than by chemical changes:
- Different particle sizes, polymorphic admixtures, hydration differences, or bound-solvent profiles can change whether a sample is “substantially” within the claimed fingerprint.
What is likely the “design-around” surface?
Given the claim language, a competitor’s main technical levers are:
- Water content / anhydrous status: avoiding “anhydrous crystalline” by maintaining bound water or forming a different solid state.
- XRPD fingerprint: producing a different polymorph or amorphous/disordered form with different peak positions/intensities.
- Bound organic solvent level: for Claim 2 avoidance, selecting a crystallization route yielding crystals that contain bound organics (or, alternatively, use a solvent system producing bound solvent species that fail “substantially free”).
- Process logic: for Claim 3 avoidance, not using the “dissolve in aqueous HCl then precipitate” route that yields the claimed form.
What does the patent say about therapeutic positioning?
The patent links the crystalline salt to:
- Inhibiting GABA uptake in a mammal in need of such treatment (Claims 6 and 7)
The claims do not limit to a specific indication (seizure type, epilepsy severity, age group). The mechanism-level method-of-use remains the scope gate.
How does US 5,958,951 fit into the broader tiagabine patent landscape?
US 5,958,951 is part of a crystalline-form and formulation layer commonly seen around classic small-molecule drugs. The landscape for tiagabine generally has these recurring buckets:
- Originator compound and stereochemistry
- Salt forms / polymorphs
- Crystal forms identified by XRPD
- Formulations and dosage forms
- Manufacturing processes
- Use and method claims (especially for known pharmacology)
Within that pattern, US 5,958,951 specifically covers:
- A crystalline anhydrous R(-)-tiagabine hydrochloride with a fingerprinted XRPD peak set
- A precipitation process from aqueous HCl
- Formulated products containing that crystalline salt
- Administration for GABA uptake inhibition
Competitive interpretation for investors
- If a generic or branded manufacturer is targeting tiagabine HCl as a solid-state product, this patent increases the probability that form selection and solid-state characterization will be the key battleground.
- If a competitor aims to market tiagabine based on a different polymorph/solvate/hydrate profile, then analytical equivalence becomes the decision point.
What is the scope risk for generic solid-state programs?
A generic entrant typically needs to establish that its solid-state form:
- is not the claimed anhydrous crystal (Claim 1/2) or
- does not meet the XRPD “substantially” peak set under the same KBr-based method
- and does not fall into the Claim 3 process route to the claimed form
If the generic uses crystallization/processing conditions that land in the same anhydrous XRPD form, the risk concentrates on:
- product matching
- bound solvent/water characterization
- and, when relevant, manufacturing process evidence.
How broad are the downstream claims (formulation and dosage)?
- Claim 4 is a standard composition claim: crystalline salt + carrier.
- Claim 5’s dosage window (about 1.0–1500 mg) is wide.
This means the downstream claims do not meaningfully limit to a narrow dose strength or formulation class; the main discriminant remains the crystal form.
What are the enforcement implications of the method-of-use claims?
Claims 6 and 7 focus on the act of administering:
- the crystalline salt (Claim 6) or the composition (Claim 7)
to inhibit GABA uptake.
For enforcement, the critical point is the identity of the active solid form actually used in the marketed product. That can shift litigation into:
- supplier documentation
- incoming solid-state specs
- and analytical lot characterization.
Key Takeaways
- US 5,958,951 is built around anhydrous crystalline R(-)-tiagabine hydrochloride defined by a specific KBr XRPD peak set: 6.4, 11.3, 13.0, 13.9, 15.0, 18.7, 19.4, 22.5, 23.7.
- Claim scope is layered: Claim 1 (anhydrous + XRPD), Claim 2 (adds “substantially free of bound organic solvent”), Claim 3 (process via aqueous HCl dissolution and precipitation), Claims 4–5 (composition + broad dosage range), and Claims 6–7 (GABA uptake inhibition method-of-use).
- The landscape risk for competitors is highest where product development lands on the same solid-state identity or uses the aqueous HCl precipitation process route that produces it.
FAQs
1) Does US 5,958,951 protect tiagabine hydrochloride broadly or only a specific crystal?
It protects a specific anhydrous crystalline R(-)-tiagabine hydrochloride defined by the listed XRPD peak set (KBr).
2) What extra limitation does Claim 2 add over Claim 1?
Claim 2 adds that the crystal is “substantially free of bound organic solvent,” while keeping the same XRPD peak set.
3) What is the critical feature of Claim 3’s process limitations?
It requires dissolving tiagabine hydrochloride in an aqueous hydrochloric acid solution and then precipitating tiagabine hydrochloride from that solution, yielding the claimed XRPD-matching anhydrous crystal.
4) Are the composition claims limited to a particular dosage strength or formulation type?
They include dosage units containing about 1.0–1500 mg of active and use standard “pharmaceutically acceptable carrier” language, leaving the crystal form as the key discriminant.
5) Can a competitor design around by changing the therapeutic claim strategy?
If the marketed product is the claimed crystalline form, the method-of-use claims are triggered by administration for GABA uptake inhibition; the most direct design-around lever remains solid-state identity.
References
[1] United States Patent and Trademark Office. “US5958951B1.” https://patents.google.com/patent/US5958951B1/en
More… ↓
⤷ Start Trial
|
